Practical methods for incorporating summary time-to-event data into meta-analysis
about
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisAdvanced management services for transient ischaemic attacks and minor strokeGranulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunctionBortezomib for the treatment of multiple myelomaAntibiotics and antiseptics for pressure ulcersAntiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndromeSubfascial endoscopic perforator surgery (SEPS) for treating and preventing recurrence of venous leg ulcersPI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerAntibiotics and antiseptics for surgical wounds healing by secondary intentionEmollients and moisturisers for eczemaPylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinomaGranulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromesIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerThe role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsMeditation for adults with haematological malignanciesErythropoiesis-stimulating agents for myelodysplastic syndromesmichGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsLow dose cytarabine monotherapy for acute myeloid leukaemiaIdiotype vaccination for Non-Hodgkin lymphomaIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersHypomethylating agents for patients with myelodysplastic syndromeThe role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationHypomethylating agents for adult patients with acute myeloid leukaemiaOzone therapy for treating foot ulcers in people with diabetesDifferent doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationRetinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaA 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcersComparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersAntiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitisPositron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaTopiramate versus carbamazepine monotherapy for epilepsy: an individual participant data reviewImmunotherapy for metastatic renal cell carcinomaAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewThrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumoursFibrin glue versus surgery for treating chronic pilonidal sinus diseaseMaintenance therapy for advanced non-small cell lung cancer (NSCLC)Rituximab for eradicating inhibitors in people with acquired haemophilia A
P2860
Q21092360-E4341D55-2E6E-49C5-8C6E-D0778B09CAE8Q21133732-B8F6AAAC-536B-4445-A9CC-855AB0883E25Q24185828-38AE51C7-D612-4CA9-A45A-B60A688BAA33Q24185847-FB269313-CF10-4427-AB8F-3F509FD23E9FQ24185881-68463E49-64EE-4B6D-BEE5-D89EC4AFA431Q24185929-8C267A4D-3932-420F-ACC2-F975828E32D6Q24185949-2BF54060-C015-4305-822A-068F72D9C2D6Q24185953-E957CA4D-AE23-4905-B173-263B7DBE329FQ24185960-78AF24C7-8A88-4868-8FAF-D2AD56D8A9F2Q24186001-FB0EAB25-F527-47DB-B43D-1A6C3C90C97CQ24186075-7F3EC57A-1E6C-4A4A-9306-B2E03C5779A5Q24186132-D7085188-026F-4447-8B2D-A08C8B888804Q24186133-9EF9CB65-2CB3-4DEE-901E-44A9386AA80EQ24186145-5351CA98-31E1-4081-8082-EF99948672C6Q24186166-CC575745-F25A-4362-8AA3-30C3829009EFQ24186169-53D9A6E8-E2BA-46C4-A350-E9E8F6D58C8DQ24186244-A81EB3B2-33AC-4695-B705-3EECF4E7ED48Q24186266-763C099E-6AAD-4E43-92D0-BDCFD0D80D52Q24186270-EAC38FF4-B848-4E14-ABF7-18FED9618B6DQ24186272-5ED97151-0A5F-4BC2-87EC-E793298ECC60Q24186274-748EDAE2-3DD0-47AB-B147-BF26800C285DQ24186276-F2201ABE-D966-4FFB-8BCB-0EAAA9E34D18Q24186279-85E1D8EC-843D-4716-BC89-E884A8549BADQ24186282-2F000F1F-40BF-4A43-A8BF-443D1DDE5AEBQ24186284-4507DA11-9A93-48D3-A6E5-BA69218FC055Q24186348-997B9826-6510-4E64-B66A-3B10C056502FQ24186359-0668170F-9D65-4E96-8FA8-F40531F32FA5Q24186451-5A0D28EF-E542-45D0-B685-C55024012533Q24186469-62EDE140-1B5A-486D-BED4-40F6937419A0Q24186471-1F0F57A0-32DA-4D00-BE5C-040FD85D4FD4Q24186615-92D1D432-790D-4214-8525-77BD4A71ACE0Q24186663-02146AC1-48FB-43F7-9DC1-5F8BAAD21D4AQ24186668-4A7E6A90-4490-4D4C-BB2C-B48DFF94A906Q24186683-8972E37F-7455-44F0-92E1-A822B29915CFQ24186688-47ABC3AC-FB07-438B-8316-FBC43FF74FAAQ24186703-FAB09829-6313-4E0B-BC89-38B53E370D40Q24186714-8950AAF9-C723-4534-A921-0D23FE485052Q24186748-D26FCA27-01EA-4FE2-8DB2-E2F41832CE22Q24186793-2743F09E-8041-4870-BD20-38AEEA6EF648Q24186862-90B6F4B6-9B20-4A26-B707-97E4DBD1F2C9
P2860
Practical methods for incorporating summary time-to-event data into meta-analysis
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Practical methods for incorporating summary time-to-event data into meta-analysis
@ast
Practical methods for incorporating summary time-to-event data into meta-analysis
@en
Practical methods for incorporating summary time-to-event data into meta-analysis
@nl
type
label
Practical methods for incorporating summary time-to-event data into meta-analysis
@ast
Practical methods for incorporating summary time-to-event data into meta-analysis
@en
Practical methods for incorporating summary time-to-event data into meta-analysis
@nl
prefLabel
Practical methods for incorporating summary time-to-event data into meta-analysis
@ast
Practical methods for incorporating summary time-to-event data into meta-analysis
@en
Practical methods for incorporating summary time-to-event data into meta-analysis
@nl
P2093
P2860
P3181
P356
P1433
P1476
Practical methods for incorporating summary time-to-event data into meta-analysis
@en
P2093
Jayne F Tierney
Lesley A Stewart
Sarah Burdett
P2860
P2888
P3181
P356
10.1186/1745-6215-8-16
P407
P577
2007-06-07T00:00:00Z
P5875
P6179
1052599734